Sanofi Teams Up with Google Life Sciences for Diabetes
Zacks Equity Research - Zacks Investment Research - Tue Sep 01, 3:45PM CDT
Sanofi (SNY) and the life sciences team at Google are collaborating for improving care and outcomes for patients with type I and type II diabetes.
GILD: 100.65 (-0.16), GOOGL: 671.24 (+4.24), SNY: 48.75 (+0.03)
Sanofi Inks Deals, Diabetes and Immuno-Oncology in Focus
Zacks Equity Research - Zacks Investment Research - Mon Aug 10, 2:15PM CDT
Sanofi (SNY) strikes agreements with Evotec and Apeiron Biologics in the area of diabetes and immuno-oncology, respectively.
GILD: 100.65 (-0.16), SNY: 48.75 (+0.03), REGN: 503.92 (+12.71)
How To Beat The Herd Mentality: Highline's Michael Higgins
Life Sciences Report - Seeking Alpha - Thu Feb 26, 2:29PM CST
Michael Higgins of Highline Research Advisors believes it is absolutely vital for a sellside biotech analyst to understand what's going on outside the sector, because no stock lives on an island. The most fabulous fundamentals in the world won't...
BDSI: 6.74 (+0.22), JNJ: 95.37 (+0.29), ESRX: 82.72 (+0.01), PFE: 33.24 (+0.15), PBM: 1.78 (+0.07), GLYC: 6.70 (+0.08), MNKD: 3.05 (+0.04), ALKS: 60.82 (+0.92), PDLI: 5.24 (+0.07)
Evotec Signs New Deal for Addictive Disorder Therapies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 20, 5:12PM CST
Evotec AG (EVTCY) entered into a research collaboration agreement with C4X Discovery Holdings plc for the development of Orexin-1 selective inhibitors.
JNJ: 95.37 (+0.29), ENDP: 64.27 (+0.85), SNY: 48.75 (+0.03)